{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021217","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.773125+00:00","generated_at":"2026-06-15T04:12:36.010163+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23","bullets":["Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.","Cash, equivalents, and short-term investments totaled $93.8M as of March 31, 2023.","Completed enrollment of pivotal STRIDE study (213 patients); topline results expected Q4 2023.","Raised $68.3M gross from public offering and private placement in May 2023.","Received FDA Fast Track designation for mavodelpar in long-chain fatty acid oxidation disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021217","json":"https://secwatch.observer/filing/0000950170-23-021217.json","markdown":"https://secwatch.observer/filing/0000950170-23-021217.md","text":"https://secwatch.observer/filing/0000950170-23-021217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/0000950170-23-021217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/rphm-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:12:36.010163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91d91948ee8430a94e6d7316fd5a848778590839","claim":"OnKure Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $15.1 million, EPS $0.60 per share.","evidence_excerpt":"We reported a net loss of $15.1 million, or $0.60 per share, during the first quarter of 2023, compared to a net loss of $13.0 million, or $0.53 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023021217/0000950170-23-021217-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"net loss of $15.1 million"},{"label":"EPS","value":"$0.60 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}